Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
(Daratumumab + hyaluronidase (human recombinant)) by Johnson & Johnson for Peripheral Neuropathy (Sensory Neuropathy): Likelihood of Approval
(Daratumumab + hyaluronidase (human recombinant)) is under clinical development by Johnson & Johnson and currently in Phase II for Peripheral...
Data Insights
(Daratumumab + hyaluronidase (human recombinant)) by Johnson & Johnson for Alzheimer's Disease: Likelihood of Approval
(Daratumumab + hyaluronidase (human recombinant)) is under clinical development by Johnson & Johnson and currently in Phase II for Alzheimer's...